Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2025 06:00 ET | Source: Alvotech

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of...
February 18, 2025 06:00 ET | Source: Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva...
February 18, 2025 06:00 ET | Source: Alvotech

Alvotech og Teva tilkynna að umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT06, fyrirhugaða hliðstæðu við augnlyfið Eylea, hafi verið tekin til umsagnar

Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharmaceuticals, bandarískt dótturfélag Teva Pharmaceutical Industries Ltd. tilkynntu í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi...
February 18, 2025 06:00 ET | Source: Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 27, 2025 06:00 ET | Source: Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 27, 2025 06:00 ET | Source: Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva...
January 27, 2025 06:00 ET | Source: Alvotech

Alvotech og Teva tilkynna að FDA hefur tekið til umsagnar umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT05, fyrirhugaða hliðstæðu við Simponi og Simponi Aria (golimumab)

Alvotech (NASDAQ: ALVO) og samstarfsaðili þess Teva Pharamceuticals, bandarískt dótturfélag Teva Pharmaceutical Industries Ltd. tilkynntu í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi...
January 03, 2025 13:00 ET | Source: Alvotech

Alvotech birtir fjárhagsdagatal fyrir árið 2025

Stefnt er að því að birting árshluta- og ársuppgjörs Alvotech og aðalfundur félagsins fari fram sem hér segir á árinu 2025: Árshlutauppgjör fjórða ársfjórðungs 2024 og ársuppgjör 202426....
December 23, 2024 04:00 ET | Source: Alvotech

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes Alvotech (NASDAQ: ALVO), a global...
December 23, 2024 04:00 ET | Source: Alvotech

Hlutabréf Alvotech tekin inn í Líftæknivístölu Nasdaq

Alvotech verður hluti af NBI vísitölunni við opnun markaða í Bandaríkjunum 23. desember 2024 Alvotech (NASDAQ: ALVO) tilkynnti í dag að hlutabréf félagsins hafi verið tekin inn í Líftæknivísitölu...